MedTrace Logo

Evaluation of Thyroid Stunning From a Diagnostic Dose of I-123

NCT02278198 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2019-10-24

No results posted yet for this study

Summary

The purpose of the study is to find out if the small dose of radioiodine, that is used for the dosimetry study on patients with differentiated thyroid cancer, may stun the cancer cells and make the thyroid cancer treatment less effective.

Conditions

  • Differentiated Thyroid Cancer

Interventions

DRUG

rhTSH

Intramuscular injections of rhTSH (Thyrogen) will be given on days 1 and 2.

Sponsors & Collaborators

  • University of Colorado, Denver

    lead OTHER

Principal Investigators

  • Jennifer Kwak, MD · Department of Radiology

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2019-09-20
Completion
2019-09-20

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02278198 on ClinicalTrials.gov